



New Frontiers in Treatment of Pancreatic Cancer

Guest Editors:

Dr. Olav F. Dajani

Department of Oncology, Oslo
University Hospital, Oslo, Norway

Dr. Knut Jørgen Labori

Department of HBP Surgery, Oslo
University Hospital, Oslo, Norway

Dr. Arne Westgaard

Department of Oncology, Oslo
University Hospital, Oslo, Norway

Deadline for manuscript
submissions:

15 November 2024

Message from the Guest Editors

Pancreatic cancer remains a challenging clinical problem. It is foreseen that the disease will become the second cause of cancer deaths in the western world. To avoid this epidemic, progress will be needed through multiple approaches. In this Special Edition, we therefore welcome original papers and reviews in the following fields of pancreatic cancer research: improved prevention and early diagnostic strategies, molecular tumor stratification for personalized and molecularly targeted antitumor treatment, and the development of rational and tolerable multimodal therapies in the neoadjuvant, adjuvant, and palliative setting, also including radiotherapy.

In addition to tumor-directed treatment, there is a great need to improve quality of life in patients with pancreatic cancer through better symptom control, such as pain management, treatment of cachexia, and psychosocial support, and we also encourage the submission of papers focusing on these.

Dr. Olav F. Dajani

Dr. Knut Jørgen Labori

Dr. Arne Westgaard

Guest Editors

